Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 75.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 585,076 shares of the biopharmaceutical company's stock after selling 1,752,641 shares during the period. Assenagon Asset Management S.A.'s holdings in Gilead Sciences were worth $54,043,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of GILD. FMR LLC boosted its holdings in Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock worth $2,780,329,000 after buying an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock worth $2,900,921,000 after acquiring an additional 11,665,593 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of Gilead Sciences by 350.1% during the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company's stock worth $193,274,000 after purchasing an additional 1,793,145 shares in the last quarter. International Assets Investment Management LLC raised its stake in Gilead Sciences by 8,238.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company's stock valued at $137,708,000 after purchasing an additional 1,622,806 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in Gilead Sciences by 24.7% in the 2nd quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company's stock valued at $541,310,000 after purchasing an additional 1,564,792 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the company's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares of the company's stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 456,234 shares of company stock valued at $42,130,461. Insiders own 0.29% of the company's stock.

Gilead Sciences Stock Down 0.8 %

Shares of NASDAQ GILD traded down $0.73 during midday trading on Thursday, hitting $91.65. The company's stock had a trading volume of 8,955,255 shares, compared to its average volume of 6,725,613. The firm has a market capitalization of $114.22 billion, a price-to-earnings ratio of 1,018.33, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The business's fifty day simple moving average is $91.97 and its two-hundred day simple moving average is $83.76.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.29 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.36%. Gilead Sciences's payout ratio is 3,422.22%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on GILD shares. Mizuho increased their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an "outperform" rating in a research report on Thursday, November 21st. Piper Sandler increased their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Citigroup assumed coverage on Gilead Sciences in a report on Thursday, November 14th. They set a "buy" rating and a $125.00 target price on the stock. Bank of America reaffirmed a "buy" rating and issued a $109.00 price target on shares of Gilead Sciences in a report on Tuesday, December 10th. Finally, Truist Financial boosted their price objective on Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research note on Friday, November 8th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.